The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million ...

MannKind's shares soared after the company revealed it has been developing a dry powder inhalation formulation of ralinepag over the past six months for United Therapeutics. Shares of MannKind climbed ...

inbrija-1 Inbrija (levodopa inhalation powder; Acorda Therapeutics) is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease ...

Biopharmaceutical company Liquidia has received tentative approval from the US Food and Drug Administration (FDA) for YUTREPIA (treprostinil) inhalation powder to treat pulmonary arterial hypertension ...

ProAir Digihaler ProAir® Digihaler® (albuterol sulfate; Teva) Inhalation Powder is now available for patients aged ≥4 years for the treatment or prevention of bronchospasm with reversible obstructive ...

MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...

March 2, 2006 — The US Food and Drug Administration (FDA) has approved orphan drug status for amphotericin B inhalation powder in the prevention of pulmonary fungal infections in patients at risk for ...

To ensure compliance with the prescribed inhaler regimen and correct inhaler administration, patients should be prescribed an inhaler that they can and will use. This is the theme of the recently ...

FDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD YUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device ...